Navigation Links
NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
Date:2/27/2008

NEW YORK, February 27 /PRNewswire-FirstCall/ -- NexGen Biofuels Ltd. (f/k/a Healthcare Technologies Ltd.) (the "Company") announced today that on February 26, 2008, the Company received a letter from the Nasdaq Listing Qualification Panel, informing the Company that the Panel had determined to delist the Company's ordinary shares from The Nasdaq Stock Market following a determination by the Staff of the Nasdaq Listing Qualifications Department that the Company had failed to meet the Nasdaq listing standards for a reverse merger in connection with the Company's Plan of Arrangement with NexGen Biofuels Inc. Nasdaq will suspend trading of the Company's ordinary shares effective at the open of business on Thursday, February 28, 2008.

The Company believes that, following the recent filing of a Form 211 by a market maker, its ordinary shares will be eligible for trading on the OTC Bulletin Board.

For more information on NexGen Biofuels, Inc., visit http://www.nexgenbiofuels.net.

Safe harbor: This press release contains certain forward looking statements within the meaning of section 27a of the securities act of 1933 and section 21e of the securities exchange act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement made by or on behalf of healthcare technologies ltd. Readers are referred to the documents filed by the company with the securities and exchange commission, specifically the form 8-k/a filed on February 12, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact: Eran Rotem CFO, +972-3-9277232


'/>"/>
SOURCE NexGen Biofuels Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
2. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
3. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
6. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
9. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web
10. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
11. HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Switzerland from December 5-10. ... Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. AxioMed ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... to their offering. ... , An increasing ... anticipated. Nanotechnology will be applied at all stages of drug ... in clinical trials. Many of the assays based on nanobiotechnology ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 01, 2016 , ... ... event is expanding to three days and will take place on February 1-3, 2017 ... (GSK) and Dr James Gulley (NCI), the program provides a unique 360-degree approach, which ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... June 27, 2016 Research and Markets has ... 2016-2020" report to their offering. ... America to grow at a CAGR of 12.28% during ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):